CALL/NOVO-NORDISK B/1400/0.1/21.06.24 | Market Closed - BOERSE MUENCHEN 05:55:53 05/06/2024 pm IST | ||
| 0.001 EUR | 0.00% |
|
| 3 months | -94.12% | ||
| 6 months | -91.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 0.001 | 0.00% |
| 04/24/04 | 0.001 | 0.00% |
| 03/24/03 | 0.001 | 0.00% |
| 31/24/31 | 0.001 | 0.00% |
| 30/24/30 | 0.001 | 0.00% |
Real-time BOERSE MUENCHEN
Last update June 05, 2024 at 05:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GQ4VDX |
| ISIN | DE000GQ4VDX7 |
| Date issued | 13/09/2023 |
| Strike | 1,400 kr |
| Maturity | 21/06/2024 (16 Days) |
| Parity | 10 : 1 |
| Emission price | 0.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.141 € |
|---|---|
| Lowest since issue | 0.001 € |
| Spread | 0.099 € |
| Spread % | 99.00% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Warrants
- Warrant
